New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
16:40 EDTTKPYYMillennium and Takeda report data from Phase I trial of ADCETRIS
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited announced results from two arms of a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed mature T-cell lymphoma, MTCL, patients, including patients with systemic anaplastic large cell lymphoma, sALCL. These data were presented at the 54th American Society of Hematology, ASH, Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate, ADC, directed to CD30. ADCETRIS is not approved for use in the front-line treatment of MTCL.
News For TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 7, 2014
13:23 EDTTKPYYSeattle Genetics, Takeda announce four-year data from ADCETRIS trial
Subscribe for More Information
12:44 EDTTKPYYSeattle Genetics, Takeda report Phase 3 AETHERA trial data from Adcetris
Subscribe for More Information
12:33 EDTTKPYYTakeda formalizes 'Takeda Oncology' to meet needs of cancer patients
Takeda Pharmaceutical announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda Oncology. The creation of Takeda Oncology will improve the company’s ability to meet the unique and urgent needs of cancer patients, their loved ones and health care providers worldwide. Takeda will sustain its long-standing entrepreneurial approach to oncology research and development while expanding its global commercial network and resources as Takeda Oncology. Takeda is retiring the Millennium: The Takeda Oncology Company brand, and replacing it with Takeda Oncology to reflect the new global oncology business unit. “Despite the progress made in the fight against cancer, serious unmet needs persist across many forms of the disease,” said Christophe Bianchi, M.D., President, Global Oncology Business Unit. “Takeda Oncology has a deep understanding of patient needs and applies scientific rigor and resources to work to meet these needs. Now, our agile business model optimally organizes us to quickly meet the diverse needs of cancer patients, health care providers and systems around the world, and bring the next generation of cancer treatments to cancer patients who need them.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use